Showing 1461-1470 of 2700 results for "".
- Kintor Pharma’s GT20029 Performs Well in Phase 1 Trial of Acne and Androgenetic Alopeciahttps://practicaldermatology.com/news/kintor-pharmas-gt20029-performs-well-in-phase-i-trial-of-acne-and-androgenetic-alopecia/2461559/Kintor Pharmaceutical Limited’s GT20029 was safe and well tolerated and had good pharmacokinetic characteristics in healthy people and people with androgenetic alopecia (AGA) or acne, according to a phase 1 clinical trial. GT20029 is the first topical PROTAC compound in the world
- Nu Skin Kicks Off Its Global Day of Service with Projects for Childrenhttps://practicaldermatology.com/news/nu-skin-kicks-off-its-global-day-of-service-with-projects-for-children/2461233/Nu Skin is hosting its 19th annual Force for Good Day to support its global humanitarian efforts. To celebrate the company's founding and to give back to local communities, each Nu Skin region sets aside a day to participate in service projects as part of its mission to b
- Joanna Zucker is New CEO at PCA Skinhttps://practicaldermatology.com/news/joanna-zucker-is-new-ceo-at-pca-skin/2460071/With more than 25 years of experience in Consumer Packaged Goods and Retail, Joanna Zucker is assuming the role of Chief Executive Officer for PCA SKIN, part of Colgate-Palmolive's professional skin care portfolio. Ms. Zucker previously served in senior management and marketing
- New Data: Aclaris' A-101 40% Safely Banishes Facial SK Lesionshttps://practicaldermatology.com/news/new-data-aclaris-a-101-40-safely-banishes-facial-sk-lesions/2458044/Good news for Aclaris. New data suggest that their drug candidate A-101 40 percent may be an appealing option to remove seborrheic keratosis (SK) lesions in highly visible areas, such as the face, with minimal risk of s
- Phase 3 Data for BF-200 ALA Presented at the 14th South Beach Symposiumhttps://practicaldermatology.com/news/phase-3-data-for-bf-200-ala-presented-at-the-14th-south-beach-symposium/2458702/Biofrontera AG’s BF-200 ALA plus red light photodynamic therapy (PDT) shows good efficacy for the treatment of actinic keratoses (AK), according to data presented from three pivotal Phase III trials at the 14th Annual South Beach Symposium. The results were presented in a poster (Poster #11
- GlobalData: Sun Pharma's Ilumya To Face Strong Competition in the US markethttps://practicaldermatology.com/news/globaldata-sun-pharmas-ilumya-will-face-strong-competition-in-the-us-market/2457816/It’s a tough road ahead for Sun Pharma’s newly approved Ilumya, according to a new report from
- Cedric Burg Named New COO at Innovadermhttps://practicaldermatology.com/news/cedric-burg-named-new-coo-at-innovaderm/2461798/Cedric Burg is Innovaderm’s new Chief Operating Officer. Mr. Burg’s new role entails the management of Innovaderm’s global operations in Canada, through the close collaboration between department heads while overseeing most of Innovaderm’s activi
- Xylyx Bio's Matrikynes Improves the Structure, Function, and Appearance of Skinhttps://practicaldermatology.com/news/xylyx-bios-matrikynes-improves-the-structure-function-and-appearance-of-skin/2461645/Xylyx Bio’s
- Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI-100https://practicaldermatology.com/news/aditxt-inc-successfully-completes-preclinical-toxicity-study-of-its-psoriasis-drug-candidate-adi-100/2461260/Aditxt, Inc.’s
- Olay Rolls Out The Olay Skin Advisor 2.0https://practicaldermatology.com/news/olay-rolls-out-the-olay-skin-advisor-20/2458270/Olay’s new